
    
      Patients with advanced NSCLC who had received nivolumab as 2nd line and beyond, between
      October 2015 and November 2019, in HeCOG clinical centres in Greece, were enrolled.
      Information regarding detailed patient and treatment characteristics including post-nivolumab
      therapies, efficacy, and safety data of nivolumab treatment and additionally data on costs
      and other economic values are collected, analysed and compared with historical data in order
      to describe the real-world patterns of Nivolumab use in 2nd line NSCLC therapy in Greece.
    
  